Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the development of innovative biopharmaceutical products, particularly in the field of vaccines and therapeutic biologics. Its competitive edge lies in its proprietary technology platforms and strong R&D capabilities, primarily focused on the Chinese market and expanding into international markets.
Olymvax generates revenue through the sale of its proprietary vaccines and therapeutic biologics, leveraging its advanced R&D capabilities to maintain pricing power. The company benefits from a high gross margin of 100%, indicating a strong competitive advantage in product development and market positioning.
Regulatory approvals for new vaccine candidates
Partnership announcements with global pharmaceutical companies
Clinical trial results for pipeline products
Market expansion into international territories
Regulatory changes impacting drug approval processes
Technological disruption in vaccine development
Emergence of new competitors in the vaccine space
Pricing pressures from established pharmaceutical companies
Moderate liquidity risk due to low free cash flow
Potential future financing needs for R&D expansion
moderate - as a biotechnology firm, Olymvax's performance is somewhat linked to overall healthcare spending, which can be influenced by GDP growth and consumer spending.
Interest rates affect Olymvax primarily through the cost of capital for R&D investments. Higher rates could increase financing costs, potentially impacting growth initiatives and valuation multiples.
minimal - the company maintains a relatively low debt-to-equity ratio of 0.47, indicating limited reliance on external credit.
growth - investors are likely drawn to the company's strong revenue growth potential and innovative product pipeline.
high - the stock has demonstrated significant price volatility, with a 1-year return of 95.8%.